FDA panel votes 3-14 that Abbott (ABT) has not found right Humira dose
- Stock Futures Higher as Scotland Votes Down Independence, Alibaba's (BABA) IPO Prices
- Twas the Night Before Alibaba (BABA)
- Pre-Open Stock Movers 9/19: (CNQR) (DRC) (JBLU) Higher; (ESI) (CRR) (TIBX) Lower (more...)
- Telefónica S.A. (TEF), Vivendi (VIVHY) Agree to $9.3B Deal for Global Village Telecom
- Are Yahoo! (YHOO) Investors Ready to 'Sell the News'? Analyst Weighs In
FDA panel votes 3-14 that Abbott (NYSE: ABT) has not found right Humira dose.
You May Also Be Interested In
- Absolute Software Provides Extended Support for iOS 8 and Apple Devices
- Heat Biologics (HTBX) Commences Dosing in HS-110 Phase 2
- Alexza Pharma (ALXA) Issues Update on Commercialization Activities for ADASUVE in Europe
Create E-mail Alert Related CategoriesFDA, General News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!